The Scout Program

An Innovative Approach to Proactively Accelerate Rett Syndrome Research is paving a new path for Rett syndrome research.  Our mission is to move discoveries to the clinic.  We have committed to fund $1,300,000 towards the Scout Program, a Drug Discovery Screen in a mouse model of Rett syndrome.

We believe that the Scout Program will aggressively accelerate the testing of compounds, whether new or repurposed, through standardized preclinical studies in the Rett mouse model.  This program will test many novel compounds and small molecules identified in leading edge research over the next two years.  The Scout Program is branched into two divisions, Academic and Pharma.

Learn more about the Scout Program [PDF]


At the 2015 Society for Neuroscience Annual meeting, the PsychoGenics team presented the poster “Assessing the Mecp2 (Bird) Model of Rett Syndrome Across Species, Sex, and Age”, which describes the battery of tests performed in the Scout Program. Click the image above to read more from the poster.

Press Releases

December 6, 2016 - Revive Therapeutics Ltd. Announces Positive Study Results in Rett Syndrome

May 20, 2016 – Anavex Announces US FDA Orphan Drug Designation to Anavex 2-73 for the Treatment of Rett Syndrome

February 25, 2016 - Positive Rett Syndrome Data from Anavex Life Science Corps
April 28, 2015 -  Revive Therapeutics Announces Positive Study Results


October 14, 2016 - A CASE STUDY OF RETTSYNDROME.ORG’S SCOUT PROGRAM HeART Awardee Bianca DeFillippis, PhD
Modulation of Rho GTPases rescues brain mitochondrial dysfunction, cognitive deficits and aberrant synaptic plasticity in female mice modeling Rett syndrome
De Filippis B, Valenti D, Chiodi V, Ferrante A, de Bari L, Fiorentini C, Domenici MR, Ricceri L, Vacca RA, Fabbri A, Laviola G.
Eur Neuropsychopharmacol. 2015 Jun;25